TLR-8 inhibitor (Dynavax/GSK)

N/A

Report date: 2025/03/20 10:00:29
NME

Base Information

Drug NameTLR-8 inhibitor (Dynavax/GSK)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionToll like receptor 8 antagonists
TargetsToll like receptor 8
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDynavax Technologies Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcDynavax Technologies Corp
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A